|Emtricitabine||Nucleoside analog reverse-transcriptase inhibitor|
|Rilpivirine||Non-nucleoside reverse transcriptase inhibitor|
|Tenofovir disoproxil fumarate||Nucleoside analog reverse-transcriptase inhibitor|
|Legal status||℞-only (US) ℞ Prescription only|
| (what is this?)
Emtricitabine/rilpivirine/tenofovir (trade name Complera, Eviplera) is a fixed dose combination of antiretroviral drugs for the treatment of HIV. The drug was co-developed by Gilead Sciences and Johnson & Johnson's Tibotec division and was approved by the Food and Drug Administration in August 2011, and by the European Medicines Agency in November 2011 (Eviplera), for patients who have not previously been treated for HIV. It is available as a once-a-day single tablet.
- "Approval of Complera: emtricitabine/rilpivirine/tenofovir DF fixed dose combination". Food and Drug Administration. August 10, 2011.
- "Eviplera; summary of the European public assessment report". European Medicines Agency. November 2011.
- "FDA approves Gilead-J&J HIV pill Complera". Business Week. August 10, 2011.
|This antiinfective drug article is a stub. You can help Wikipedia by expanding it.|